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lines to NKG2D-dependent cell killing exerted by natural killer
and cd T cells; 6) they can also reduce in vitro the metabolism
and growth of RS cells. Inhibition of cleavage of other ADAM10
substrates, such CD30, a target for antibody-based anti-lym-
phoma therapy, might also be useful in HL. Thus, we think that
selective ADAM10 inhibitors may be proposed as part of anti-
lymphoma therapeutic schemes and contribute to the enhance-
ment of anti-tumor immune response.
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Background: Cancerogenesis occurs against deterioration of
immunosurveillance and growing immunodeficiency. This
requires addition of adjuvant treatment correcting immune sta-
tus in patients. It was postulated that polyphenol substances
yield positive effects on cancer pathogenesis exerting anti-prolif-
erative, DNA-damaging, anti-angiogenic, anti-metastatic and
other functions.
Purpose: To assess prospectively the immunomodulating effect
of novel polyphenol substance Melanin on cytokine profile in
patients with advanced urological cancer in the adjuvant setting.
Methods: Fifteen random patients with advanced urological
cancer (kidney, bladder, prostate) scheduled for cancer treat-
ment (surgery, chemotherapy) were administered Melanin from
yeast-like fungi Nadsoniella nigra sp. X1 (Antarctica), one capsule
(10 mg) twice daily for 30 days after initiation of treatment. Con-
trols were twenty random uro-oncological patients of identical
clinical stages subjected for the same treatment protocol, receiv-
ing placebo, and ten healthy individuals. We drew plasma sam-
ples in all groups at the beginning of the study and after
1 month of treatment. We analyzed serum cytokines (IL-1b, IL-
12, IFN-c, TNF-a, IL-4 and IL-10) by ELISA.
Results: Administration of Melanin in study group caused sta-
tistically significant changes in cytokine profile. The pro-inflam-
matory IL-1b dropped by 24 %, IFN-c rose by 50 %, and IL-12
stayed unchanged. All anti-inflammatory cytokines showed
increase: TNF-a rose by 184 %, IL-4 rose by 44 %, and IL-10 rose
by 85 %.
Conclusions: Application of novel polyphenol substance Mela-
nin 10 mg as cancer treatment adjuvant in patients with
advanced urological cancer exerts evident immunomodulating
effect, affecting the level of cytokines in peripheral blood. Con-
sidering state of decreased immunosurveillance, studied
polyphenol substance may be considered a beneficial immune-
rehabilitative compound deserving further study of its biochem-
ical and clinical effects.
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Development of neuropathic syndrome limits anticancer ther-
apy with oxaliplatin. Increasing evidence indicates that complex
mechanisms and maladaptive plasticity of the central nervous
system, including central sensitization, are involved in the
pathophysiology of chemotherapy-induced neuropathies. The
insufficient information on the pathophysiology and molecular
basis of the chemotherapy-induced peripheral neuropathy is an
important limit to the development of new effective treatments.
In a rat model of oxaliplatin-induced neuropathy, we found
that activation of presynaptic P2X7 receptors for ATP evoked
an increased glutamate release from cerebrocortical nerve termi-
nals. The release was abolished by the P2X7 antagonists Bril-
liant-Blue-G and A-438079, and reduced by carbenoxolone and
the Pannexin1 selective inhibitors erioglaucine and 10Panx, sug-
gesting the recruitment of the accessory protein Pannexin1.
Aimed to evaluate the significance of P2X7-Pannexin1 system
activation in pain induced by oxaliplatin, pharmacological mod-
ulators were intrathecally infused in oxaliplatin-treated animals.
Brilliant-Blue-G, erioglaucine and 10Panx reverted oxaliplatin-
induced pain. Finally, the influence of the P2X7-Pannexin1 sys-
tem blockade on oxaliplatin anticancer activity was evaluated
on the human colon cancer cell line HT-29. Prevention of HT-
29 apoptosis and mortality was dependent on concentration of
P2X7R antagonists. On the contrary, the inhibition of Pannexin1
did not alter oxaliplatin lethality in tumor cells.
In summary, glutamate release dependent on P2X7 receptor is
increased in cerebrocortical nerve terminals from oxaliplatin-
treated rats; the increase is mediated by functional recruitment
of the accessory protein Pannexin1; P2X7 antagonists and Pan-
nexin1 inhibitors revert oxaliplatin-induced neuropathic pain;
Pannexin1 inhibitors did not alter the oxaliplatin-induced mor-
tality of cancer cells HT-29. In conclusion, our results highlight
the relevance of P2X7-Panx1 complex in the maladaptive
response of central nervous system to oxaliplatin neurotoxicity.
P2X7 receptor- Pannexin1 participates in alteration of neuronal
functions leading to central sensitization and pain chroniciza-
tion. The selective inhibition of Pannexin1 channel is suggested
as new pharmacological target for oxaliplatin-induced neuro-
pathic pain relief.
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Transcription factor p53 is a well-known oncosuppressor protein
with thoroughly explored role in cancer. However, recent
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advances suggest that both p53 and its negative regulator
MDM2 might be involved in autoimmune processes. Inhibition
of MDM2 (i.e. by small molecule Nutlin-3a) and associated acti-
vation of p53 are considered as a promising therapeutic
approach for treatment of autoimmune diseases, i.e. multiple
sclerosis.
In the current study we compared Nutlin-3a-induced expres-
sion of p53-dependent genes (p21, mdm2 and PUMA) in periph-
eral blood mononuclear cells (PBMCs) from patient diagnosed
with multiple sclerosis (MS) and a healthy volunteer. The results
indicate that gradual increase of Nutlin-3a concentration (5uM,
10uM, 20uM, 40uM) leads to higher expression levels of p21,
mdm2 and PUMA genes in MS samples compared to healthy
control. These preliminary data suggest that the transcription
functions of p53 protein might be enhanced in patients with
MS. Data obtained by TaqMan real-time PCR technique using
CFX96 Touch Detection System (Bio-Rad). The study was
funded by RFBR research grant 16-34-60213 mol_а_dk.
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There are growing evidences that etiology and pathogenesis of
essential hypertension and prostate cancer include autoimmune
component. However, autoantigens involved in these processes
are still largely unknown. Separated fragments of tyrosyl-tRNA
synthetase (TyrRS) miniTyrRS and C-terminal domain (CTD)
provide non-canonical functions such as immune cell signaling
and can potentially serve as autoantigen.
The aim of the study was to investigate antibodies to full-
length TyrRS and its domains in sera of patients with essential
hypertension and prostate cancer.
Patients with essential hypertension and prostate cancer, as
well as healthy subjects were recruited to participate in the
study. The recombinant proteins generated by Escherichia coli
were purified by chromatography on Ni-NTA-agarose. Specific
autoantibodies (aAbs) were measured by ELISA and confirmed
in an immunoblotting assay. From 6% to 12% of subjects with
elevated levels of aAbs against the full-length enzyme were
detected in all the cohorts studied. 52 % of patients with essen-
tial hypertension were identified as immunoreactive against
miniTyrRS and 50 % - against CTD (P << 001). In 418 % of indi-
viduals with prostate cancer the levels of anti-CTD aAbs were
elevated, meanwhile, only 22,4% of these oncology patients were
immunoreactive for miniTyrRS (P <<001).
We propose that autoantibodies to Tyrosyl-tRNA synthetase
and their fragments provide one of the triggers for autosensibi-
lization in essential hypertension and prostate cancer which may
well extend to other autoimmune disease in humans.
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Background: Mucosa-associated lymphoid tissue is the largest
reserve of immune cells along the gastro-intestinal system to
front microorganisms that are confined in gut lumen by a thin
epithelial barrier. In colorectal cancer (CRC) mucosa equilibrium
is subverted becoming antigen-permeable, switching-on a strong
inflammatory response that can inhibit the anti-tumor T-cells
response. COX-2, the key enzyme of PGE2 synthesis, and IL8
are highly expressed in CRC and linked to bad prognosis. Both
factors can recruit immunosuppressive cells and recent studies
showed a correlation between COX-2 and IL8 mRNA in CRC
samples, though their relation has neither been investigated at
protein level, nor used for defining CRC clusters.
Methods: COX-2 and IL8 modulation by IL1b, IL17 and IL22
were tested in vitro both on CRC cell lines and on primary
CRC-associated fibroblasts (CAF) to identify different responses
of cancer and stromal cells. COX-2, IL8 and IL1b were also mea-
sured in 100 human CRC specimens by quantitative western blot
and ELISA. Their expression was related to each other and to
clinicopathologic parameters to define clusters of tumors with
a different immune-modulatory microenvironment.
Results: We found that IL1b strongly induces a synchronous
expression of COX-2 and IL8 in CAF, while its activity in cancer
cells is lower and cell line-specific. We also observed that IL22 is
active only on cancer cells, triggering STAT-3 and down-regulat-
ing COX-2.
Protein analysis of CRC samples identified two subsets of
tumors: one where COX-2 and IL8 are modulated in tandem
and associated with IL1b levels, the other with dominant
COX-2 or IL8 alone, showing a more aggressive phenotype
(prevalence of stage IV/worse prognosis).
Conclusions: The evaluation of COX-2/IL8 balance in primary
tumors represents a new criterion for CRC patients clustering
after surgery, providing a rationale for the experimentation of
immune-modulatory targeted therapies according to a defined
cytokine balance.
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Purpose: Anti-PD-1 or anti-PD-L1 blocking monoclonal anti-
bodies (mAbs) have shown potent anti-tumor effects in mouse
tumors and adult cancer patients. Clinical studies have recently
been started in pediatric cancers, including high-risk or relaps-
ing neuroblastoma (NB).
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